APDN insider filing: CEO now holds 18,695 common shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Applied DNA Sciences reported an insider equity change. The Chief Executive Officer filed a Form 4 showing acquisition of 18,691 shares of common stock on 10/17/2025 at a price of $0, coded “A.” Following the transaction, the officer beneficially owned 18,695 shares, held directly.
The filing notes that 100% of the related restricted stock units vest 90 days from the date of grant.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Shorrock Clay
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 18,691 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 18,695 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What did APDN disclose in this Form 4?
The CEO acquired 18,691 shares of common stock on 10/17/2025 at $0, coded “A,” and now holds 18,695 shares directly.
Who is the reporting person in APDN’s Form 4?
An Officer of the company, serving as Chief Executive Officer.
What does the transaction code 'A' mean for APDN’s Form 4?
It indicates an acquisition of securities, recorded at a price of $0 for the common stock reported.
What is the vesting detail mentioned for APDN?
The filing states that 100% of the restricted stock units vest 90 days from the date of grant.
What is the security reported for APDN in this filing?
Common Stock was reported in Table I; no derivative securities were listed in Table II.